Skin Inflammation Clinical Trial
— AvoSkinOfficial title:
A Pilot Study to Determine the Effect of Avocado Consumption on Skin Aging
Verified date | October 2021 |
Source | University of California, Los Angeles |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This clinical trial aims to assess the effect of providing one avocado per day on skin health in comparison with a control group maintaining their habitual diets. Participants will be randomly assigned to one of two equally sized groups. Both groups will be instructed to continue to follow their habitual diet but the intervention group will receive one avocado per day. Participants will be followed for outcomes for a four-month period.
Status | Completed |
Enrollment | 40 |
Est. completion date | December 30, 2020 |
Est. primary completion date | December 30, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 25 Years to 90 Years |
Eligibility | Inclusion Criteria: - Female subjects - Increased waist circumference defined as =35 inches for women (NCEP ATP III 2005) - Women - At least 25 years old at screening - Not currently eating more than 2 avocados per month (habitual intake in U.S.) - Non-smokers - Fitzpatrick Skin type II-IV - Willing to maintain their normal skin care pattern for the duration of the study (avoiding excessive sun, not beginning new skin treatments) - Subjects must read and sign the Institutional Review Board-approved written informed consent prior to the initiation of any study specific procedures or enrollment Exclusion Criteria: - Does not eat avocados - Sensitive / allergic to avocados - Allergies to latex or oral allergy syndrome - Not willing or unable to undergo MRI scans - Unstable medical condition such as on dialysis for renal disease, cardiac, gastrointestinal, or hepatic disease, cancer (non-melanoma skin cancer >5 years ago acceptable, any cancer site >10yrs without recurrence). - Pregnant, lactating, intention of pregnancy - Lost or gained 10 lbs of body weight in last year - Following restricted or weight loss dietary patterns - Subjects who cannot avoid excessive exposure to either natural or artificial sunlight. - Unstable anti-anxiety / anti-depressive / anti-psychotic medication use defined as dose change within last 6 months - Currently taking any prescription medications that increase the risk of photosensitivity or history of taking such medications in the less than 3 months (e.g. alpha-hydroxy acids in cosmetics, antibiotics (ciprofloxacin, doxycycline, levofloxacin, ofloxacin, tetracycline, trimethoprim), antifungals (flucytosine, griseofulvin, voricanozole), antihistamines (cetirizine, diphenhydramine, loratadine, promethazine, cyproheptadine), Accutane - Oral steroid use within the last 6 months longer than 7 days - Elevated alcohol intake (7+ drinks/week females; 14+ drinks/week males) - Participation in another clinical intervention trial within 30 days of baseline |
Country | Name | City | State |
---|---|---|---|
United States | UCLA Center for Human Nutrition | Los Angeles | California |
Lead Sponsor | Collaborator |
---|---|
University of California, Los Angeles | Hass Avocado Board |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Minimal erythema | Standardized inflammation will be induced by irradiating test areas on the inner arm of subjects with defined doses of narrow band ultraviolet B (NB-UVB) light delivered by the Dermalight 90 handheld device (National Biological). | 16 weeks | |
Primary | Skin Elasticity | The Cutometer measures the vertical deformation of the skin in millimeters when the skin is pulled by means of a controlled vacuum into the circular aperture, 6mm in diameter, of the probe. In its standard configuration, the Cutometer is equipped with a measuring probe with a 2mm aperture because the device is originally designed to measure only the elastic properties of the epidermis. Skin hydration will measured using the moisture/hydration probe that attaches to the Cutometer. We will measure six sites: forehead, under the eye, frontal cheek, crow's foot, lateral cheek, and inner forearm. | 16 weeks | |
Secondary | Skin Type Classification | Developed in 1975, the system classifies skin type according to the amount of pigment the skin has and the skin's reaction to sun exposure. This information can help predict your overall risk of sun damage and skin cancer. | 16 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04479514 -
Preventative Skin Care for Children Undergoing Targeted CNS Tumor Therapy
|
Phase 2 | |
Completed |
NCT03065504 -
Turmeric and Turmeric-containing Tablets and Sebum Production
|
N/A | |
Recruiting |
NCT05535738 -
Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation
|
Phase 2/Phase 3 | |
Recruiting |
NCT05277324 -
The Effect of Wearing Facial Masks on Skin Parameters During the COVID-19 Pandemic
|
||
Completed |
NCT05300542 -
Efficacy Study of a Novel Skin Health Product to Reduce an UVB Induced Erythema
|
N/A | |
Completed |
NCT05745636 -
Broccoli Seed Extract and Skin Health
|
N/A | |
Completed |
NCT03192280 -
Skin IaM: An Exploratory Clinical Trial to Evaluate Changes in Skin Appearance, Colour, and/or Texture Following the Induction of a Local Inflammatory Skin Response
|
N/A | |
Withdrawn |
NCT03976206 -
Very Small Embryonic-like Stem Cells for Facial Skin Antiaging
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03862872 -
Effects of Bend Beauty's Anti-Aging Formula on Inflammatory Markers
|
N/A | |
Completed |
NCT04471896 -
Joovvin' for Your Skin Health Study
|
N/A | |
Recruiting |
NCT03581747 -
Detection of Skin Epithelial Barrier in Patients With Allergic Skin Disorders
|
||
Recruiting |
NCT06387212 -
35 kDa Hyaluronan Fragment (HA35) Reduces Chronic Inflammation of Skin
|
N/A | |
Completed |
NCT05517720 -
An Exploratory Investigation of a Novel Skincare Regimen
|
N/A | |
Completed |
NCT05461456 -
Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1%
|
Phase 1 |